Jubilant Ingrevia reported record Q2 FY27 revenue of Rs 1,394 crore, marking a 24% year-on-year growth. Net profit jumped 60% to Rs 111 crore, driven by strong performance across its specialty chemicals and nutrition segments. The company also announced a strategic 40% stake acquisition in Zettaone Technologies for Rs 189 crore to enter the electronics manufacturing space.
Jubilant Ingrevia Posts Record Revenue of Rs 1,394 Crore
Net Profit Climbs 60% YoY to Rs 111 Crore
Reader Takeaway: Strong segment growth drives record earnings, but integration of the new electronics acquisition remains a key watch point.
What just happened
Jubilant Ingrevia reported its highest-ever quarterly revenue of Rs 1,394 crore for Q2 FY27, a 24% increase from the previous year. EBITDA saw a substantial 51% year-on-year rise to Rs 221 crore, the best performance in three years. The company's net profit reached Rs 111 crore, reflecting a 60% growth compared to the same period last year.
Why this matters
The company is successfully scaling its core business while diversifying into high-growth sectors. All three core segments showed double-digit revenue growth: Specialty Chemicals grew 16%, Nutrition and Health Solutions surged 50%, and Chemical Intermediates rose 24%. These results provide momentum for management to target the upper end of its annual guidance.
Strategic Acquisition: Zettaone Technologies
Jubilant Ingrevia has entered into an agreement to acquire a 40% stake in Zettaone Technologies for Rs 189 crore. This move marks the company's foray into electronics design and manufacturing services, specifically targeting the semiconductor supply chain. Management expects Zettaone to see 60%-70% growth this year, adding a new strategic vertical to the current chemical portfolio.
Growth Pipeline and Capex
The company currently has a pipeline of over 25 confirmed molecules with a peak revenue potential of Rs 1,500 crore, excluding its major CDMO contract. When including the CDMO project, the potential revenue climbs toward Rs 2,000 crore. To support this growth, Jubilant Ingrevia has earmarked an annual capital expenditure of Rs 400-500 crore, with the new Gajraula multipurpose plant slated for commissioning by year-end.
Risks to watch
Management noted persistent pricing pressure on base pyridine and B3 products, which is expected to influence Q3 results. Furthermore, the company must successfully navigate the operational integration of the Zettaone business and ensure the timely ramp-up of its CDMO contract to meet the projected revenue targets.